Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug cocktail aims to shrink tumors before surgery, boost survival after

NCT ID NCT04208347

Summary

This study is testing whether adding two newer drugs (apatinib and camrelizumab) to standard chemotherapy helps people with advanced stomach cancer. The treatment is given both before surgery to shrink the tumor and after surgery to try to prevent the cancer from coming back. Researchers will measure if the combination leads to better survival and fewer side effects compared to chemotherapy alone.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Affiliated Hospital of Hebei University

    Baoding, China

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, China

  • Cancer Hospital of the University of Chinese Academy of Sciences

    Hangzhou, China

  • Changhai Hospital

    Shanghai, China

  • First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China

  • Hainan Cancer Hospital

    Haikou, China

  • Hefei Cancer Hospital, Chinese Academy of Sciences

    Hefei, China

  • Henan Provincial Cancer Hospital

    Zhengzhou, China

  • Heping Hospital Affiliated to Changzhi Medical College

    Changzhi, China

  • Jilin Guowen Hospital

    Siping, China

  • Lanzhou University Second Hospital

    Lanzhou, China

  • Liaoning Cancer Hospita & Institute

    Shenyang, China

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, China

  • Shanxi Provincial Cancer Hospital

    Taiyuan, China

  • Sichuan Cancer Hospital & Institute

    Chengdu, China

  • Sichuan Provincial People's Hospital

    Chengdu, China

  • Tangdu Hospital

    Xi'an, China

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, China

  • Xiangya Hospital Central South University

    Changsha, China

  • Yantai Yuhuangding Hospital

    Yantai, China

Conditions

Explore the condition pages connected to this study.